Sign Up to like & get
recommendations!
0
Published in 2017 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.12503
Abstract: Enzalutamide is an androgen receptor inhibitor approved for treatment of metastatic castrationāresistant prostate cancer. Enzalutamide is highly protein bound and eliminated primarily by hepatic metabolism; therefore, it is important to understand whether enzalutamide pharmacokinetics is…
read more here.
Keywords:
comparison pharmacokinetics;
subjects hepatic;
safety enzalutamide;
hepatic impairment ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e14073
Abstract: e14073Background: Enzalutamide (ENZ), an androgen receptor inhibitor, is approved in over 60 countries except China for use in metastatic castration-resistant prostate cancer. The PK of ENZ have be...
read more here.
Keywords:
safety enzalutamide;
healthy chinese;
chinese males;
enzalutamide healthy ... See more keywords